Revance Therapeutics Inc (RVNC)

[Lishur]

Under the terms of the agreement, Revance will receive an upfront payment of $30 million within 30 business days of entering into the license agreement and is eligible to receive additional potential development and sales milestone payments of up to $230.5 million, as well as tiered low-double-digit to high-teen royalty payments on future net sales.

China market is supposed to grow up to 700 million a year by 2027..if approved.. RVNC can make let's say 15 per cent of whatever Fosun sells every year..plus the milestone payment